Rotavirus
Rotavirus, the most common diarrheal pathogen in children worldwide, causes approximately one third of diarrhea-associated hospitalizations and 800,000 deaths per year. Because natural infection reduces the incidence and severity of subsequent episodes, rotavirus diarrhea might be controlled through...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Centers for Disease Control and Prevention
1998-12-01
|
Series: | Emerging Infectious Diseases |
Subjects: | |
Online Access: | https://wwwnc.cdc.gov/eid/article/4/4/98-0406_article |
id |
doaj-f5aedc9199984656b7f1bbba9dde9a45 |
---|---|
record_format |
Article |
spelling |
doaj-f5aedc9199984656b7f1bbba9dde9a452020-11-24T22:07:38ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60591998-12-014456157010.3201/eid0404.980406RotavirusUmesh D. ParasharJoseph S. BreseeJon R. GentschRoger I. GlassRotavirus, the most common diarrheal pathogen in children worldwide, causes approximately one third of diarrhea-associated hospitalizations and 800,000 deaths per year. Because natural infection reduces the incidence and severity of subsequent episodes, rotavirus diarrhea might be controlled through vaccination. Serotype-specific immunity may play a role in protection from disease. Tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) (which contains a rhesus rotavirus with serotype G3 specificity and reassortant rhesus-human rotaviruses with G1, G2, and G4 specificity) provides coverage against the four common serotypes of human rotavirus. In clinical trials in industrialized countries, RRV-TV conferred 49% to 68% protection against any rotavirus diarrhea and 61% to 100% protection against severe disease. This vaccine was licensed by the U.S. Food and Drug Administration on August 31, 1998, and should be cost-effective in reducing diarrheal diseases in industrialized countries. The vaccine's efficacy and cost-effectiveness in developing countries should be evaluated.https://wwwnc.cdc.gov/eid/article/4/4/98-0406_articleUnited States |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Umesh D. Parashar Joseph S. Bresee Jon R. Gentsch Roger I. Glass |
spellingShingle |
Umesh D. Parashar Joseph S. Bresee Jon R. Gentsch Roger I. Glass Rotavirus Emerging Infectious Diseases United States |
author_facet |
Umesh D. Parashar Joseph S. Bresee Jon R. Gentsch Roger I. Glass |
author_sort |
Umesh D. Parashar |
title |
Rotavirus |
title_short |
Rotavirus |
title_full |
Rotavirus |
title_fullStr |
Rotavirus |
title_full_unstemmed |
Rotavirus |
title_sort |
rotavirus |
publisher |
Centers for Disease Control and Prevention |
series |
Emerging Infectious Diseases |
issn |
1080-6040 1080-6059 |
publishDate |
1998-12-01 |
description |
Rotavirus, the most common diarrheal pathogen in children worldwide, causes approximately one third of diarrhea-associated hospitalizations and 800,000 deaths per year. Because natural infection reduces the incidence and severity of subsequent episodes, rotavirus diarrhea might be controlled through vaccination. Serotype-specific immunity may play a role in protection from disease. Tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) (which contains a rhesus rotavirus with serotype G3 specificity and reassortant rhesus-human rotaviruses with G1, G2, and G4 specificity) provides coverage against the four common serotypes of human rotavirus. In clinical trials in industrialized countries, RRV-TV conferred 49% to 68% protection against any rotavirus diarrhea and 61% to 100% protection against severe disease. This vaccine was licensed by the U.S. Food and Drug Administration on August 31, 1998, and should be cost-effective in reducing diarrheal diseases in industrialized countries. The vaccine's efficacy and cost-effectiveness in developing countries should be evaluated. |
topic |
United States |
url |
https://wwwnc.cdc.gov/eid/article/4/4/98-0406_article |
work_keys_str_mv |
AT umeshdparashar rotavirus AT josephsbresee rotavirus AT jonrgentsch rotavirus AT rogeriglass rotavirus |
_version_ |
1725819459979968512 |